Bushi G, Gaidhane S, Ballal S, Kumar S, Bhat M, Sharma S
Health Sci Rep. 2025; 8(2):e70490.
PMID: 39980820
PMC: 11839483.
DOI: 10.1002/hsr2.70490.
Benjamin D, Von Hoff D
Cancer Drug Resist. 2025; 7:49.
PMID: 39931650
PMC: 11810457.
DOI: 10.20517/cdr.2024.116.
Altea-Manzano P, Decker-Farrell A, Janowitz T, Erez A
Nat Rev Cancer. 2025; .
PMID: 39833533
DOI: 10.1038/s41568-024-00786-4.
Li D, Chen Y, Zhu X, Yang Y, Li H, Zhao R
J Biomed Sci. 2025; 32(1):6.
PMID: 39773638
PMC: 11708274.
DOI: 10.1186/s12929-024-01098-3.
Islam K, Islam R, Tong V, Shami M, Allen K, Brodtmann J
Cureus. 2024; 16(10):e71875.
PMID: 39559664
PMC: 11573306.
DOI: 10.7759/cureus.71875.
Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among patients with diabetes.
Grandhi N, Liu L, Wang M, Thomas T, Schoen M, Sanfilippo K
JNCI Cancer Spectr. 2024; 8(6).
PMID: 39514091
PMC: 11643351.
DOI: 10.1093/jncics/pkae095.
GLP-1 Receptor Agonists and Risk of Paralytic Ileus: A drug-target Mendelian Randomization Study.
Ding P, Gao Z, Gorenflo M, Xu R
medRxiv. 2024; .
PMID: 39484277
PMC: 11527067.
DOI: 10.1101/2024.10.17.24315627.
Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients.
Quagliariello V, Canale M, Bisceglia I, Iovine M, Giordano V, Giacobbe I
Int J Mol Sci. 2024; 25(20).
PMID: 39457081
PMC: 11508560.
DOI: 10.3390/ijms252011299.
Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.
Wang W, Wang Q, Qi X, Gurney M, Perry G, Volkow N
Alzheimers Dement. 2024; 20(12):8661-8672.
PMID: 39445596
PMC: 11667504.
DOI: 10.1002/alz.14313.
Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data.
Wang L, Wang Q, Li L, Kaelber D, Xu R
J Natl Cancer Inst. 2024; 117(3):476-485.
PMID: 39418202
PMC: 11884861.
DOI: 10.1093/jnci/djae260.
The Interlinking Metabolic Association between Type 2 Diabetes Mellitus and Cancer: Molecular Mechanisms and Therapeutic Insights.
Asiri A, Al Qarni A, Bakillah A
Diagnostics (Basel). 2024; 14(19).
PMID: 39410536
PMC: 11475808.
DOI: 10.3390/diagnostics14192132.
Association Between GLP-1 Receptor Agonists and Incidence of Lung Cancer in Treatment-Naïve Type 2 Diabetes.
Song J, Cali Daylan A, Chi K, Prem Anand D, Chang Y, Chiang C
J Gen Intern Med. 2024; .
PMID: 39365528
DOI: 10.1007/s11606-024-09076-z.
Risk of Esophageal and Gastric Cancer in Patients with Type 2 Diabetes Receiving Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A National Analysis.
Ayoub M, Aibani R, Dodd T, Ceesay M, Bhinder M, Faris C
Cancers (Basel). 2024; 16(18).
PMID: 39335195
PMC: 11430483.
DOI: 10.3390/cancers16183224.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND).
Brown S, Tadros A, Montagna G, Bell T, Crowley F, Gallagher E
Front Pharmacol. 2024; 15:1457363.
PMID: 39318780
PMC: 11420520.
DOI: 10.3389/fphar.2024.1457363.
Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance.
De Fano M, Malara M, Vermigli C, Murdolo G
Int J Mol Sci. 2024; 25(16).
PMID: 39201336
PMC: 11354636.
DOI: 10.3390/ijms25168650.
Comprehensive Evaluation of a Levonorgestrel Intrauterine Device (LNG-IUD), Metformin, and Liraglutide for Fertility Preservation in Endometrial Cancer: Protocol for a Randomized Clinical Trial.
Leipold G, Toth R, Harsfalvi P, Loczi L, Torok M, Keszthelyi A
Life (Basel). 2024; 14(7).
PMID: 39063589
PMC: 11278026.
DOI: 10.3390/life14070835.
Non-Insulin Antidiabetic Agents and Lung Cancer Risk in Drug-Naive Patients with Type 2 Diabetes Mellitus: A Nationwide Retrospective Cohort Study.
Tabernacki T, Wang L, Kaelber D, Xu R, Berger N
Cancers (Basel). 2024; 16(13).
PMID: 39001440
PMC: 11240387.
DOI: 10.3390/cancers16132377.
Associations between Diabetes Mellitus and Selected Cancers.
Pliszka M, Szablewski L
Int J Mol Sci. 2024; 25(13).
PMID: 39000583
PMC: 11242587.
DOI: 10.3390/ijms25137476.
Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes.
Wang L, Xu R, Kaelber D, Berger N
JAMA Netw Open. 2024; 7(7):e2421305.
PMID: 38967919
PMC: 11227080.
DOI: 10.1001/jamanetworkopen.2024.21305.
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer.
Ibrahim S, Ibrahim R, Arabi B, Brockmueller A, Shakibaei M, Busselberg D
Cancer Metastasis Rev. 2024; 43(4):1297-1314.
PMID: 38801466
PMC: 11554930.
DOI: 10.1007/s10555-024-10192-9.
